212 related articles for article (PubMed ID: 30588194)
1. Cancer/testis Antigen MAGEA3 Interacts with STAT1 and Remodels the Tumor Microenvironment.
Wang Y; Song X; Zheng Y; Liu Z; Li Y; Qian X; Pang X; Zhang Y; Yin Y
Int J Med Sci; 2018; 15(14):1702-1712. PubMed ID: 30588194
[TBL] [Abstract][Full Text] [Related]
2. Immunological and functional aspects of MAGEA3 cancer/testis antigen.
Das B; Senapati S
Adv Protein Chem Struct Biol; 2021; 125():121-147. PubMed ID: 33931137
[TBL] [Abstract][Full Text] [Related]
3. Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling.
Marijt KA; Sluijter M; Blijleven L; Tolmeijer SH; Scheeren FA; van der Burg SH; van Hall T
J Immunother Cancer; 2019 Jun; 7(1):152. PubMed ID: 31196219
[TBL] [Abstract][Full Text] [Related]
4. Functional and mechanistic studies reveal MAGEA3 as a pro-survival factor in pancreatic cancer cells.
Das B; Senapati S
J Exp Clin Cancer Res; 2019 Jul; 38(1):294. PubMed ID: 31287009
[TBL] [Abstract][Full Text] [Related]
5. Regulation of XAF1 expression in human colon cancer cell by interferon beta: activation by the transcription regulator STAT1.
Sun Y; Qiao L; Xia HH; Lin MC; Zou B; Yuan Y; Zhu S; Gu Q; Cheung TK; Kung HF; Yuen MF; Chan AO; Wong BC
Cancer Lett; 2008 Feb; 260(1-2):62-71. PubMed ID: 18035482
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma.
Craig AJ; Garcia-Lezana T; Ruiz de Galarreta M; Villacorta-Martin C; Kozlova EG; Martins-Filho SN; von Felden J; Ahsen ME; Bresnahan E; Hernandez-Meza G; Labgaa I; D'Avola D; Schwartz M; Llovet JM; Sia D; Thung S; Losic B; Lujambio A; Villanueva A
PLoS Genet; 2021 Jun; 17(6):e1009589. PubMed ID: 34166362
[TBL] [Abstract][Full Text] [Related]
7. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment.
Zemek RM; De Jong E; Chin WL; Schuster IS; Fear VS; Casey TH; Forbes C; Dart SJ; Leslie C; Zaitouny A; Small M; Boon L; Forrest ARR; Muiri DO; Degli-Esposti MA; Millward MJ; Nowak AK; Lassmann T; Bosco A; Lake RA; Lesterhuis WJ
Sci Transl Med; 2019 Jul; 11(501):. PubMed ID: 31316010
[TBL] [Abstract][Full Text] [Related]
8. miR-1273g silences MAGEA3/6 to inhibit human colorectal cancer cell growth via activation of AMPK signaling.
Wu F; Liu F; Dong L; Yang H; He X; Li L; Zhao L; Jin S; Li G
Cancer Lett; 2018 Oct; 435():1-9. PubMed ID: 30056111
[TBL] [Abstract][Full Text] [Related]
9. Cancer testis antigen MAGEA3 in serum and serum-derived exosomes serves as a promising biomarker in lung adenocarcinoma.
Gan Y; Kang Y; Zhong R; You J; Chen J; Li L; Chen J; Chen L
Sci Rep; 2024 Mar; 14(1):7573. PubMed ID: 38555374
[TBL] [Abstract][Full Text] [Related]
10. Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells.
Hix LM; Karavitis J; Khan MW; Shi YH; Khazaie K; Zhang M
J Biol Chem; 2013 Apr; 288(17):11676-88. PubMed ID: 23486482
[TBL] [Abstract][Full Text] [Related]
11. The clinical significance of MAGEA3 expression in pancreatic cancer.
Kim J; Reber HA; Hines OJ; Kazanjian KK; Tran A; Ye X; Amersi FF; Martinez SR; Dry SM; Bilchik AJ; Hoon DS
Int J Cancer; 2006 May; 118(9):2269-75. PubMed ID: 16331618
[TBL] [Abstract][Full Text] [Related]
12. Infrequent and low expression of cancer-testis antigens located on the X chromosome in colorectal cancer: implications for immunotherapy in South African populations.
Dakshinamurthy AG; Ramesar R; Goldberg P; Blackburn JM
Biotechnol J; 2008 Nov; 3(11):1417-23. PubMed ID: 18956367
[TBL] [Abstract][Full Text] [Related]
13. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma.
Camicia R; Bachmann SB; Winkler HC; Beer M; Tinguely M; Haralambieva E; Hassa PO
J Cell Sci; 2013 May; 126(Pt 9):1969-80. PubMed ID: 23487038
[TBL] [Abstract][Full Text] [Related]
14. The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression.
Ahn R; Sabourin V; Bolt AM; Hébert S; Totten S; De Jay N; Festa MC; Young YK; Im YK; Pawson T; Koromilas AE; Muller WJ; Mann KK; Kleinman CL; Ursini-Siegel J
Nat Commun; 2017 Mar; 8():14638. PubMed ID: 28276425
[TBL] [Abstract][Full Text] [Related]
15. IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells.
Carbotti G; Nikpoor AR; Vacca P; Gangemi R; Giordano C; Campelli F; Ferrini S; Fabbi M
J Exp Clin Cancer Res; 2017 Oct; 36(1):140. PubMed ID: 29020964
[TBL] [Abstract][Full Text] [Related]
16. The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration.
Perea F; Bernal M; Sánchez-Palencia A; Carretero J; Torres C; Bayarri C; Gómez-Morales M; Garrido F; Ruiz-Cabello F
Int J Cancer; 2017 Feb; 140(4):888-899. PubMed ID: 27785783
[TBL] [Abstract][Full Text] [Related]
17. Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line.
Dovhey SE; Ghosh NS; Wright KL
Cancer Res; 2000 Oct; 60(20):5789-96. PubMed ID: 11059775
[TBL] [Abstract][Full Text] [Related]
18. Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.
Hemminger JA; Toland AE; Scharschmidt TJ; Mayerson JL; Guttridge DC; Iwenofu OH
Mod Pathol; 2014 Sep; 27(9):1238-45. PubMed ID: 24457462
[TBL] [Abstract][Full Text] [Related]
19. CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response.
Qadir AS; Ceppi P; Brockway S; Law C; Mu L; Khodarev NN; Kim J; Zhao JC; Putzbach W; Murmann AE; Chen Z; Chen W; Liu X; Salomon AR; Liu H; Weichselbaum RR; Yu J; Peter ME
Cell Rep; 2017 Mar; 18(10):2373-2386. PubMed ID: 28273453
[TBL] [Abstract][Full Text] [Related]
20. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
